Moneycontrol PRO
Open App
Upcoming Event: Finterest EduTech Technical Analysis Programme in Oct, book your seats.
you are here: HomeNewsTrendsHealth

Sputnik V, Sputnik Light booster effective against Omicron: RDIF

Sputnik Light booster is recommended to strengthen the efficacy of vaccines against Omicron, RDIF noted.

December 18, 2021 / 08:58 AM IST
Sputnik V has been authorised in 71 countries with a total population of over 4 billion people. (Representative image)

Sputnik V has been authorised in 71 countries with a total population of over 4 billion people. (Representative image)

Russian Direct Investment Fund (RDIF) on December 17 said a preliminary laboratory study conducted by the Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster were effective against the Omicron variant of COVID-19. Heterologous boosting with Sputnik Light is the solution to increase other vaccines' efficacy, including against Omicron, and extend the booster protection period, RDIF said in a statement.

Sputnik Light as a booster significantly increases virus neutralising activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response, it added.

Sputnik Light booster is recommended to strengthen the efficacy of vaccines against Omicron, RDIF noted.

Boosting by Sputnik Light as well as heterologous boosting can strengthen and lengthen the quickly waning efficacy of many vaccines in light of combined Delta and Omicron challenge, it added.

Sputnik Light has already been registered in more than 20 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, UAE, Bahrain, the Philippines, and San Marino).

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Also read | Delhi logs 12 new cases of Omicron; most fully vaccinated, asymptomatic

Sputnik V has been authorised in 71 countries with a total population of over 4 billion people.

RDIF is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors.
PTI
first published: Dec 18, 2021 08:57 am
Sections
ISO 27001 - BSI Assurance Mark